Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most core label-consistent claims are supported (indications for neuropathic pain, fibromyalgia, and adjunctive partial-onset seizures; gradual taper when discontinuing; labeled adverse effects such as dizziness/somnolence and rebound/withdrawal-type symptoms). However, several statements are not supported by the provided label excerpts, particularly detailed switching/taper-and-ramp-up guidance, specific alternative drugs for replacement options, and several regulatory/market exclusivity statements unrelated to prescribing information.
Category Scores
Accurate Statements
Lyrica is pregabalin.
LYRICA (pregabalin); active ingredient listed.
Pregabalin is used for neuropathic pain, including diabetic nerve pain.
Section 1: management of neuropathic pain associated with diabetic peripheral neuropathy.
Pregabalin is used for fibromyalgia.
Section 1: management of fibromyalgia.
Pregabalin is used for certain seizure disorders.
Section 1: adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.
Do not stop Lyrica (pregabalin) suddenly.
Section 2.1 and Warnings/Precautions 5.6: withdraw/taper gradually over a minimum of 1 week when discontinuing.
Pregabalin is typically tapered when changing therapy.
Section 2.1 and 5.6: when discontinuing, taper gradually over a minimum of 1 week.
Tapering is used to reduce withdrawal symptoms.
Section 5.6: symptoms following abrupt/rapid discontinuation; instruct to taper gradually.
Tapering is used to avoid rebound symptoms.
Section 5.6 supports avoiding adverse symptoms after abrupt/rapid discontinuation; specific term 'rebound' not quoted but concept of return/worsening of symptoms after abrupt discontinuation is consistent with the provided excerpted withdrawal symptom list.
Rebound symptoms after stopping pregabalin can include return or worsening of pain.
Supported indirectly by 5.6 listing symptoms after abrupt/rapid discontinuation including insomnia, nausea, headache, anxiety, hyperhidrosis, diarrhea; however the provided excerpt does not explicitly list 'pain return/worsening'—so this specific element is only partially supported by provided text (marked elsewhere).
Switching increases the chance of side effects such as sleepiness.
Label excerpts: 5.5 dizziness and somnolence; 6.1 dizziness (4%) and somnolence (4%).
Switching increases the chance of side effects such as dizziness.
5.5 dizziness and somnolence; 6.1 dizziness (4%).
Switching increases the chance of side effects such as weight gain.
5.8 Weight Gain: LYRICA treatment may cause weight gain.
The chance of side effects such as sleepiness, dizziness, and weight gain is especially early in the change.
Not explicitly supported in provided excerpts; cannot be verified from supplied text.
Neuropathic pain replacement options may include gabapentin.
Not supported in provided label excerpts.
For seizures (adjunct therapy in adults), other anti-seizure medicines may be used depending on diagnosis and past response.
Adjunctive therapy indicated; label excerpt provided does not explicitly discuss selecting other anti-seizure medicines.
Gabapentin and pregabalin are not the same drug.
Not discussed in provided LYRICA label excerpts; cannot be verified from provided label text.
They are related in how they work and are often used in similar situations.
Not supported in provided LYRICA label excerpts.
Unsupported Statements
Gabapentin is a common alternative to pregabalin for neuropathic pain.
No information about gabapentin as an alternative is present in the provided label excerpts.
They are related in how they work and are often used in similar situations.
No comparative mechanism/usage statements between pregabalin and gabapentin are present in the provided label excerpts.
Gabapentin and pregabalin are not the same drug.
The provided label excerpts for LYRICA do not address gabapentin or whether they are the same drug.
Dosing is not interchangeable one-for-one when switching between pregabalin and gabapentin.
No guidance on switching between pregabalin and gabapentin or interchangeability is included in the provided label excerpts.
Switching from pregabalin to gabapentin typically requires a planned taper of the old dose and a ramp-up of the new one.
No switching/ramp-up guidance and no gabapentin-specific conversion language is provided in the excerpts.
Tapering and ramp-up are used to reduce withdrawal symptoms and side effects like dizziness or sedation.
Label excerpts provide tapering guidance for discontinuation (5.6) but do not provide ramp-up guidance nor the rationale phrased specifically around switching to gabapentin.
A pregabalin brand-to-generic switch or switching between different strengths/formulations may occur as a replacement option.
No brand-to-generic or formulation switching replacement language is present in the provided label excerpts.
Switching between brand and generic products or between different strengths/formulations can matter for people who are sensitive to dose changes or excipients.
No excipient sensitivity or brand/generic switching statements are present in the provided label excerpts.
Generic pregabalin products are often a main answer for finding a cheaper alternative.
No pricing/market statements exist in prescribing information excerpts.
DrugPatentWatch.com tracks drug patent and exclusivity information.
Not part of FDA-approved prescribing information.
Generic entry is expected or already occurred when a brand's exclusivity has ended.
Not part of FDA-approved prescribing information.
Rebound symptoms after stopping pregabalin can include anxiety.
Label excerpt 5.6 lists anxiety among symptoms following abrupt/rapid discontinuation, but the provided claim frames it as 'rebound symptoms' after stopping; while consistent with discontinuation symptoms, the specific term 'rebound symptoms' is not used in the provided excerpts.
Rebound symptoms after stopping pregabalin can include insomnia.
5.6 lists insomnia following abrupt/rapid discontinuation, but again the excerpt does not use 'rebound' terminology.
Rebound symptoms after stopping pregabalin can include seizure risk in people using it for epilepsy.
The provided excerpts do not link discontinuation 'rebound' to seizure risk specifically.
The chance of side effects such as sleepiness, dizziness, and weight gain is especially early in the change.
No timing ('especially early') language is present in provided label excerpts.
Neuropathic pain replacement options may include duloxetine.
No statements about duloxetine as a replacement option are present in the provided LYRICA label excerpts.
Neuropathic pain replacement options may include amitriptyline.
No statements about amitriptyline as a replacement option are present in the provided LYRICA label excerpts.
Fibromyalgia replacement options may include duloxetine.
No statements about duloxetine as a replacement option are present in the provided LYRICA label excerpts.
Fibromyalgia replacement options may include amitriptyline.
No statements about amitriptyline as a replacement option are present in the provided LYRICA label excerpts.
Fibromyalgia replacement options may include gabapentin.
No statements about gabapentin as a replacement option are present in the provided LYRICA label excerpts.
Fibromyalgia replacement options may include pregabalin dose/formulation adjustments.
While dosing adjustments exist for pregabalin within its indication (Section 2.5), this is framed as a 'replacement option' rather than within-indication titration; switching guidance to treat fibromyalgia is not stated as 'replacement options.'
For seizures (adjunct therapy in adults), other anti-seizure medicines may be used depending on diagnosis and past response.
Label excerpt provided does not discuss selection of other anti-seizure medications.
Contradictions
Low
AI Statement
Switching from pregabalin to gabapentin typically requires a planned taper of the old dose and a ramp-up of the new one.
Label Reference
No contradiction can be confirmed because the provided label excerpts do not address pregabalin-to-gabapentin switching; classification as contradiction is not supported. (Reported as non-supported instead.)
Important Omissions
No mention of labeled contraindication: hypersensitivity to pregabalin or components (Section 4).
Importance:
Moderate
No mention of boxed warning (if any) or key warnings/precautions beyond abrupt discontinuation (e.g., suicidal behavior/ideation, respiratory depression with CNS depressants, dizziness/somnolence impairment, angioedema/hypersensitivity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements extend beyond the provided prescribing information (e.g., gabapentin switching/ramp-up details; alternative replacement options; seizure-risk rebound framing; timing of side effects). While tapering/discontinuation caution is label-supported, unsupported switching narratives could mislead about proper transition practices.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are unsupported by the provided FDA label excerpts, especially detailed switching guidance between pregabalin and gabapentin and lists of replacement options (duloxetine/amitriptyline/gabapentin) not mentioned in the provided labeling.
Suggested Improvement
Limit claims to on-label indications and label-supported discontinuation guidance; remove or qualify unsupported switching and replacement-option statements unless supported by the label text provided.